Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

X will start adding parody labels to accounts and posts as the company tries to add some form of transparency to the platform ...

In February 2016, a gangland murder in broad-daylight shocked the nation of Ireland, and it involved the uncle of a young man ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

To the Filipino doctor's utter dissapointment, he did not receive any financial compensation for his milestone discovery.

Eli Lilly & Company to establish new global capability centre in Hyderabad, recruiting over 1,000 professionals for advanced ...